Urolog. pro Praxi, 2008; 9(1): 10-15 [Klin Farmakol Farm. 2007;21(3):114-118]

Hormonal regulations and possibilities of intervention in prostate cancer treatment

MUDr. Kamil Belej FEBU2, MUDr. Ondřej Kaplan1,2
1 Urologické oddělení, Klaudiánova nemocnice, Mladá Boleslav
2 Urologické oddělení Ústřední vojenská nemocnice, Praha

Since pivotal studies in 40´s of 20th century, hormonal therapy become the mainstay for the management of patiens with locally advanced and metastatic prostate cancer. In recent years, however, there has been an evolution towards increasing hormonal treatment of younger men with lower stage of disease or recurrent disease after definitive treatment. It is frequently used as a part of a multimodality approach.

Keywords: prostate, carcinoma, hormons, androgens

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Belej K, Kaplan O. Hormonal regulations and possibilities of intervention in prostate cancer treatment. Urol. praxi. 2008;9(1):10-15.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brinkmann AO, Faber PW, van Rooj HCJ et al. The human androgen receptor: domain, structure, genomic organization and regulation of expression. J Steroid Biochem Mol Biol 1989; 34: 307-310. Go to original source... Go to PubMed...
    2. Culig Z, Hobisch A, Bartsch G, Klocker H. Androgen receptor - an update of mechanisms of action in prostate cancer. Urol Res 2000; 28: 211-219. Go to original source... Go to PubMed...
    3. Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 2007; v tisku (doi: 10.1210/me.2007-0223). Go to original source... Go to PubMed...
    4. Dobs A, Darkes MJ. Incidence and management of gynecomastia in men treated for prostate cancer. J Urol 2005; 174 (5): 1737-1742. Go to original source... Go to PubMed...
    5. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
    6. Huirne JAF, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001; 358: 1793-1803. Go to original source... Go to PubMed...
    7. Ip C, Hall SJ. Hormonal implications in the development and treatment of prostate cancer. Endocrinol Metab Clin North Am 2007; 36 (2): 421-434. Go to original source... Go to PubMed...
    8. Labrie F. Multiple intracrine hormonal targets in the prostate: opportunities and challenges. BJU International 2007; 100 (s2): 48-51. Go to original source... Go to PubMed...
    9. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate 2003; 57: 134-139. Go to original source... Go to PubMed...
    10. Martin AW, Coffey DS. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In: Walsh, PC, Retik, A, Vaughan, ED, Wein, AJ (Eds.). Campbell's Urology, W. B. Saunders, Philadelphia, PA, 1998, 1381-1428.
    11. Oefelein MG, Feng A, Scolieri MJ et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56: 1021-1024. Go to original source... Go to PubMed...
    12. Rossi D, Cornu JN, Roupret M. LHRH agonists in prostate cancer. Prog Urol 2007; 17 (2 Suppl 1): 287-290.
    13. Steers, WD. 5 alpha-reductase activity in the prostate. Urology 2001; 58 (6 Suppl 1): 17-24. Go to original source... Go to PubMed...
    14. Tombal B, Jasienski S, Debie B et al. Is there a significant difference in testosteron level after surgical castration, goserelin or triptorelin? Eur Urol 2007; 6 (2): 29, abstr. 260. Go to original source...
    15. White JW. The results of double castration in hypertrophy of the prostate. Ann Surg 1895; 22: 1-80. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.